Minesh P. Mehta, MD
Professor, Department of Human Oncology
School of Medicine and Public Health
University of Wisconsin
Roy A Patchell, MD
Chief of Neuro-Oncology
Professor of Neurosurgery and Neurology
University of Kentucky Medical Center
Michael A. Vogelbaum, MD, PhD
Associate Director, Neurosurgical Oncology
Brain Tumor and Neuro-Oncology Center
Cleveland Clinic Neurological Institute
Physician CME: 1.5
CREDIT FOR THIS PROGRAM IS AVAILABLE TO PHYSICIANS, ONLY.
This online capture of a satellite symposium was originally presented on November 14, 2007, in conjunction with the 12th annual scientific meeting of the Society for Neuro-Oncology (SNO). If you received credit from the live symposium, you are not eligible to apply for credit through this online version.
Being diagnosed with a primary glioma or metastatic brain tumor often carries a dismal prognosis but newer advances in surgery, radiation therapy, chemotherapy, and combination chemoradiation offer hope. In a field for which there are few absolute standards of care, however, there is debate over which approaches would be best for each individual patient. Is there just one optimal treatment modality for a particular patient? Are several different approaches reasonable? Or are there some novel solutions that merit further discussion and exploration?
Realistic cases of anaplastic glioma with and without chromosome 1p and 19q co-deletions are discussed as well as cases involving single and multiple metastases. Using an audience response system, symposium participants were asked to vote on clinical options. Our prestigious panel of experts in neuro-oncology, radiation oncology, and neurosurgery compare the audience’s treatment choices with their own, discussing the benefits and limitations of each. Program Developer/Facilitator
. Target Audience
This educational activity is designed to meet the needs of neuro-oncologists, neurosurgeons, radiation oncologists, and medical oncologists interested in the treatment of primary and metastatic brain tumors.
Upon completion of this educational activity, the participant should be able to:
Discuss the impact of 1p/19q co-deletion on management of Grade III gliomas.
Describe differing treatments for single brain lesions compared to multiple brain metastases.
Delineate potential toxicities and adverse effects associated with various treatment regimens.
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity.
This educational activity may contain discussion of published and/or investigational uses of oncology agents. Some uses may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Dr. Mehta discloses advisory committee participation for Allos, product consultation for Pharmacyclics, and speakers’ bureau service for Schering-Plough. He intends to discuss unapproved/investigational uses of pharmacologic products or surgical devices.
Dr. Patchell claims no actual or potential conflict of interest to this program. He intends to discuss unapproved/investigational uses of pharmacologic products or surgical devices.
Dr. Vogelbaum discloses advisory committee and speakers’ bureau participation for Schering-Plough Corporation. He intends to discuss unapproved/investigational uses of pharmacologic products or surgical devices.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH, Inc. and Medical Communications Media, Incorporated. AKH, Inc. is accredited by the ACCME to provide continuing medical education for physicians.
AKH, Inc. designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Participants must successfully complete the post-test (70% or higher) and submit an evaluation to receive credit. There is no fee to participate and receive credit.
Commercial Support Statements
This activity is supported by an educational grant from Schering-Plough.
Please turn off all pop-up blockers and click on the "Start Program" icon. If you have not previously registered with this website, you will be taken to the login/registration page where you will be able to register as a new CMEcorner.com member. If you have previously registered, you will be asked to verify or correct existing registration information. When ready, click on the "Start Program" icon.
The next screen will permit you to check for or download the Flash player required to run this program. Clicking on the "slides" button on this screen will begin the program presentation. This program, question-and-answer session, post-test, and evaluation will take approximately 90 minutes to complete.
Instructions for completing and submitting the post-test are provided on the post-test screen. A minimum score of 70% on the post-test is required for a CME certificate. One retake is permitted.
©2008 Medical Communications Media, Inc. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this publication and in the related educational event are those of the presenters and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., the Society for Neuro-Oncology, or Schering-Plough. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other healthcare professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.